Evidence map›Paper›PMID 41957583›Full record

ReviewMolecular medicine (Cambridge, Mass.)2026

Emerging significance of E3 ubiquitin ligases and Deubiquitinases in pulmonary hypertension.

Chao-Wei Ding, Jia-Yong Qiu, Hui Shen, Yi Yan, Ze-Xin Liu, Shen-Shen Huang, Yue-Jiao Ma, Zhi-Cheng Jing

Abstract readReview
In one paragraph

Review in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chao-Wei Ding *Department of Respiratory and Critical Care Medicine, Xiamen Humanity Hospital of Fujian Medical University, Xiamen, 361000, China.
Jia-Yong Qiu *Department of Cardiovascular Medicine,Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, No. 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Hui ShenDepartment of Cardiology, Affiliated Hospital of Yangzhou University, Yangzhou University, Institute of Cardiovascular Disease, Yangzhou Key Lab of Innovation Frontiers in Cardiovascular Disease, Yangzhou, 225000, China.
Yi YanHeart Center, Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Ze-Xin LiuDepartment of Respiratory and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Shen-Shen HuangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Yue-Jiao MaDepartment of Cardiovascular Medicine,Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, No. 106 Zhongshan 2nd Road, Guangzhou, 510080, China. myuejiao@163.com.
Zhi-Cheng JingDepartment of Cardiovascular Medicine,Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, No. 106 Zhongshan 2nd Road, Guangzhou, 510080, China. jingzhicheng@vip.163.com.

Funding

Medical Science Research Project of Hebei 20250046National Key Research and Development Program of China 2022YFC2703900 and 2022YFC2703902National Natural Science Foundation of China 82241020National Natural Science Foundation of China 82300080Non-communicable Chronic Diseases-National Science and Technology Major Project 2024ZD0526700Shenzhen Medical Research Fund C2404001
6 · The paper itself

Abstract

Pulmonary hypertension (PH) is a progressive, life-threatening cardiovascular disorder. It features irreversible pulmonary vascular remodeling and causes right ventricular failure and mortality. The underlying pathogenesis of PH is incompletely elucidated. Ubiquitination is a reversible post-translational modification. It regulates protein degradation and membrane trafficking and contributes critically to PH development and progression. The ubiquitin-proteasome system (UPS), especially E3 ubiquitin ligases and Deubiquitinases, modulates the function of pulmonary artery endothelial cells and pulmonary artery smooth muscle cells in PH. These molecules exert distinct roles and regulatory mechanisms in PH-related signaling pathways. The pathways include bone morphogenetic protein, nuclear factor kappa B (NF-κB), hypoxia inducible factor-1α, P53, Hippo, and mitochondrial quality control. UPS-targeted small-molecule agents, proteasome inhibitors, and proteolysis-targeting chimeras have therapeutic potential for PH. They also face notable translational challenges. Ubiquitination provides new mechanistic insights into PH pathogenesis and identifies innovative avenues for targeted therapy.

Indexed as

Deubiquitinating EnzymesHypertension, PulmonaryUbiquitin-Protein LigasesAnimalsHumansProteasome Endopeptidase ComplexSignal TransductionUbiquitinationDeubiquitinating EnzymesProteasome Endopeptidase ComplexUbiquitin-Protein LigasesDeubiquitinationPulmonary hypertensionTherapeutic targetsUbiquitinationUbiquitin ligase

Identifiers

PMID41957583
PMCPMC13202862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.